HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $61 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $61 price target.
HC Wainwright & Co. Reiterates Buy on First Wave BioPharma, Maintains $18 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy and maintains $18 price target.
RBC Capital Reiterates Outperform on Nuvei, Maintains $50 Price Target
RBC Capital analyst Paul Treiber reiterates Nuvei (NASDAQ:NVEI) with a Outperform and maintains $50 price target.
RBC Capital Reiterates Outperform on Parex Resources, Maintains C$28 Price Target
RBC Capital analyst Luke Davis reiterates Parex Resources (TSX:PXT) with a Outperform and maintains C$28 price target.
RBC Capital Reiterates Outperform on Kiwetinohk Energy, Maintains C$20 Price Target
RBC Capital analyst Michael Harvey reiterates Kiwetinohk Energy (TSX:KEC) with a Outperform and maintains C$20 price target.
RBC Capital Reiterates Sector Perform on Conifex Timber, Maintains C$2 Price Target
RBC Capital analyst Paul Quinn reiterates Conifex Timber (TSX:CFF) with a Sector Perform and maintains C$2 price target.
Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target
Credit Suisse analyst Judah Frommer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $4 price target.
Credit Suisse Reiterates Outperform on Dover, Maintains $174 Price Target
Credit Suisse analyst Guy Hardwick reiterates Dover (NYSE:DOV) with a Outperform and maintains $174 price target.
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.
EF Hutton Reiterates Buy on Troika Media Group, Maintains $1.5 Price Target
EF Hutton analyst Michael Albanese reiterates Troika Media Group (NASDAQ:TRKA) with a Buy and maintains $1.5 price target.